In summary, the HMGCLL1 gene polymorphism is a novel genetic biomarker for intrinsic sensitivity to IM therapy in CML patients that predicts DMR in this setting.
The present study demonstrates that the HMGCLL1 genetic variant is a powerful predictive biomarker for intrinsic sensitivity to TKI therapy that correlates with DMR rate in CML patients.
Cemazar M, Miklavcic D, Sersa G. Intrinsic sensitivity of tumor cells to bleomycin as an indicator of tumor response to electrochemotherapy. Jpn J Cancer Res.
Herein, we report that an HMGCLL1 genetic variant located in 6p12.1 can be used as a predictive genetic biomarker for intrinsic sensitivity to imatinib (IM) therapy.
Intrinsic sensitivity of the proposed sensor is significantly high for almost entire range of RH values.
Numerous other contributing factors should also be considered, such as chemotherapeutic agents, smoking, tumor topography, or intrinsic sensitivity.
In contrast, range expansions at the leading edge are related to a combination of species attributes linked to their intrinsic sensitivity, but also to their resilience ability to track optimal conditions.
Of clinical relevance, this genetic biomarker can be used to identify the cases expected to have poor intrinsic sensitivity to IM therapy even prior to commencement of TKI therapy.
Given the observed wide spectrum of intrinsic sensitivity to TKI therapy among patients with CML, identification of a genetic biomarker that can predict DMR following TKI therapy could be of clinical value.
Common for the three groups of work is a combination of international orientation, particularly Nordic/North European developments, and an intrinsic sensitivity to contextuality.
The photoluminescence (PL) characteristics of semiconductor quantum dots (QDs) and their intrinsic sensitivity to their surrounding environment have made them an attractive material set for sensing applications.
